VC-backed Crux Biomedical has agreed to be acquired by Volcano Corporation, a developer of medical devices and technologies used to treat coronary and peripheral vascular disease. Both companies have focused their attention on treating issues related to the human vascular system. Crux, a Menlo Park, Calif.-based company, is responsible for creating an innovative device used for the treatment of pulmonary embolisms. Per the agreement’s terms, Volcano will pay $36 million in cash at the time of closing. Exiting investors include Alloy Ventures, Three Arch Partners, Emergent Medical Partners and angel investor Thomas Fogarty, M.D.